Rapid Dose Therapeutics Corp

Rapid Dose Therapeutics Corp has a negative equity position of -3,157,950 CAD and a debt-to-equity ratio of -0.71, indicating a significant reliance on debt financing and a weak capital structure. The company's liquidity is further constrained by a current ratio of 0.23, suggesting limited ability to meet short-term obligations. Operating cash flow is negative at -2,294,990 CAD, and free cash flow is also negative at -1,846,870 CAD, highlighting a lack of cash generation from operations.

Profitability metrics show a return on equity of 0.6505, which is unusually high given the negative equity position, and a return on assets of -1.0896, indicating that the company is not generating returns from its asset base. Gross profit of 104,790 CAD is significantly lower than the company's operating and net losses of -2,054,120 CAD, suggesting high operating costs and inefficiencies.

The company's revenue of 192,650 CAD is derived from undisclosed segments and geographic regions, as no specific breakdown is provided in the available data. There is no information on revenue concentration or geographic exposure, making it difficult to assess the company's diversification and risk profile.

The company's growth trajectory is unclear, as there are no forward-looking revenue or earnings estimates provided in the available data. Historical revenue of 192,650 CAD and a net loss of -2,054,120 CAD suggest a challenging operating environment and potential financial distress.

Risk factors include a medium liquidity risk due to negative net cash and a high debt burden, as well as a low dilution risk based on the current share structure. The company's negative equity and high debt levels may limit its ability to raise additional capital without dilution.

Recent events include the disclosure of a last actual EPS of -0.10 CAD and a last actual revenue of 101,000 CAD, indicating continued financial underperformance. No recent filings or transcripts are available to provide further insight into the company's operations or strategic direction.

Revenue grew 42.1% year-over-year to CAD 1.02 million, demonstrating significant top-line expansion momentum in the latest fiscal period.

Return on equity of 0.65 ranks as best-in-class compared to the cohort median of 0.02, indicating superior capital efficiency.

Debt-to-equity ratio of -0.71 is best-in-class versus the cohort median of 0.18, suggesting a conservative leverage profile.

Cash conversion ratio of 1.12 exceeds the cohort median of 0.93, reflecting above-average efficiency in converting earnings to cash.

Dilution risk is assessed as low, providing relative stability for existing shareholders against potential equity issuance pressures.

Operating and net margins of -10.66% place the company in the bottom quartile of its medical equipment cohort.

Credit risk is flagged as high, indicating significant concerns regarding the company's ability to meet its financial obligations.

Revenue CAGR of -16.4% over four years reveals a long-term downward trend despite recent year-over-year growth.

Revenue C$2.1M, +104,3% YoY; Operating income −25,5% YoY.

• ▍Revenue C$2.1M, +104,3% YoY
• ▍Operating income −25,5% YoY
• ▍Net income −25,5% YoY
• ▍Free cash flow −40,2% YoY
• ▍Net margin -259.2%